by jtcir-auto | May 16, 2022 | Press Releases
TORONTO, ON, May 16, 2022 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today...
by jtcir-auto | May 12, 2022 | Press Releases
– Data presented at IMMUNOLOGY2022™, the Annual Event of the American Association of Immunologists – Company advancing development of its Autoimmunity Modifying (“AIM”) Biologicals as a potential therapeutic treatment option for...
by jtcir-auto | May 11, 2022 | Press Releases
– Continued advancement across diversified development pipeline – Company ended the quarter with $63.6 million in cash, expected to fund operations through 2023 TORONTO, ONTARIO, May 11, 2022 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS)...
by jtcir-auto | May 11, 2022 | Press Releases
– Continued advancement across diversified development pipeline – Company ended the quarter with $63.6 million in cash, expected to fund operations through 2023 TORONTO, ONTARIO, May 11, 2022 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS)...
by jtcir-auto | Apr 25, 2022 | Press Releases
– Company advancing development of its Autoimmunity Modifying AIM Biologicals as a potential therapeutic treatment option for Parkinson’s Disease (“PD”), a neurodegenerative movement disorder TORONTO, ONTARIO, April 25, 2022 (GLOBE NEWSWIRE)...